Emphysematous Cholecystitis

Overview

Emphysematous cholecystitis is a rare but life-threatening form of acute cholecystitis characterized by the presence of gas within the gallbladder lumen, wall, or surrounding biliary structures. Distinct from gallstone-induced cholecystitis in both pathophysiology and epidemiology, this condition is associated with substantially higher morbidity and mortality and occurs most frequently in individuals with diabetes mellitus or immunocompromising conditions. Prompt recognition and treatment are essential because delayed diagnosis can lead to severe complications and poor clinical outcomes. This course reviews the pathogenesis, risk factors, clinical presentation, diagnostic evaluation, imaging findings, and management of emphysematous cholecystitis. Participants learn to identify characteristic features of the disease, differentiate it from other biliary disorders, and apply evidence-based treatment strategies for timely intervention. Collaboration among clinicians, surgeons, radiologists, nurses, and other healthcare professionals enhances diagnostic accuracy, expedites treatment, improves care coordination, and supports better patient outcomes through comprehensive multidisciplinary management.

Target Audience

This activity has been designed to meet the educational needs of physicians, physician associates, nurses, pharmacists, and nurse practitioners.

Learning Objectives

At the conclusion of this activity, the learner will be better able to:

  • Compare the epidemiology, pathophysiology, clinical presentation, imaging findings, and outcomes of emphysematous cholecystitis with those of uncomplicated acute cholecystitis.
  • Determine appropriate diagnostic modalities, the urgency of intervention, and management strategies based on the patient's presentation and disease progression.
  • Assess patient risk factors, clinical manifestations, comorbidities, and disease severity associated with emphysematous cholecystitis, particularly in individuals with diabetes mellitus or immunocompromising conditions.
  • Develop interprofessional communication and collaborative management strategies among clinicians, surgeons, radiologists, nurses, infectious disease specialists, and allied healthcare professionals to optimize care coordination and patient outcomes.
  • Outline the pharmacologic therapy as it applies to Emphysematous Cholecystitis.

Disclosures

StatPearls, LLC requires everyone who influences the content of an educational activity to disclose relevant financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant conflict(s) of interest have been mitigated. Hover over contributor names for financial disclosures. Others involved in planning this educational activity have no relevant financial relationships to disclose.

Commercial Support: This activity has received NO commercial support.

Continuing Education Accreditation Information

In support of improving patient care, StatPearls, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Nurse Practitioners: StatPearls designates this activity for 1.00 ANCC contact hour(s), which includes 0.5 hour(s) of pharmacology. NPs should only claim credit commensurate with the extent of their participation in the activity.
Please consult your professional licensing board for information on the applicability and acceptance of continuing education credit for this activity.

Method of Participation and Credit

  1. Register for the activity.
  2. Review the target audience, learning objectives, and disclosure information.
  3. Study the educational content of the enduring material.
  4. Choose the best answer to each activity test question. To receive credit and a certificate, you must pass the test questions with a minimum score of 100%.
  5. Complete the post-activity assessment survey.